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ABSTRACT 
Riluzole, the only drug available against amyotrophic lateral sclerosis (ALS), has 
recently been shown to block muscle ACh receptors (AChR), raising concerns about 
possible negative side-effects on neuromuscolar transmission in treated patients. In 
this work we studied riluzole impact on the function of muscle AChR in vitro and on 
neuromuscular transmission in ALS patients, using electrophysiological techniques. 
Human recombinant AChR composed by α1β1δ subunits plus γ or ε subunits (γ- or ε-
AChR) were expressed in HEK cells or Xenopus oocytes. In both preparations, 
riluzole at a clinically relevant concentration reversibly reduced the amplitude and 
accelerated the decay of ACh-evoked current if applied before coapplication with 
ACh. The action on γ-AChR was more potent and faster than on ε-AChR. In HEK 
outside-out patches, riluzole-induced block of macroscopic ACh-evoked current 
gradually developed during the initial milliseconds of ACh presence. Single channel 
recordings in HEK cells and in human myotubes from ALS patients showed that 
riluzole prolongs channel closed time, but has no effect on channel conductance and 
open duration. Finally, compound muscle action potentials (CMAPs) evoked by nerve 
stimulation in ALS patients remained unaltered after a 1-week suspension of riluzole 
treatment. These data indicate that riluzole, while apparently safe on synaptic 
transmission, may affect the function of AChR expressed in denervated muscle fibres 
of ALS patients, with biological consequences that remain to be investigated. 
 
 
ABBREVIATIONS 
AChR, acetylcholine receptor; ALS, amyotrophic lateral sclerosis; CMAP, compound 
muscle action potential; EGFP, enhanced green fluorescent protein; IACh, ACh-evoked 
whole-cell current; QACh, integral of ACh-evoked whole-cell current; PKC, protein 
kinase C. 
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INTRODUCTION 
 
Riluzole is the only drug currently registered to treat patients with Amyotrophic 
Lateral Sclerosis (ALS), a fatal disease due to selective degeneration of upper and/or 
lower motoneurones. The compound has several adverse side effects, among which 
asthenia, that further decrease patients' quality of life, so that a full assessment of its 
effects might help in devising countermeasures. Riluzole affects the function of a 
variety of ion channels in neurones and possibly in muscle (Bellingham et al., 2011). 
In particular, when co-administered with ACh, it impairs the function of recombinant 
mouse acetylcholine receptors (AChR), although only at very high concentrations 
(Mohammadi et al., 2002), well beyond the range found in patients' serum (0.5 to 5 
µM; Bellingham et al., 2011). Conversely, our group recently observed a strong block 
of AChR function by clinically used concentrations of riluzole in human muscle 
preparations obtained from ALS or denervated patients, provided that riluzole was 
applied before the transmitter (Palma et al., 2011). Since AChRs mediate nerve-
muscle communication at the neuromuscular junction and are chronically exposed to 
riluzole in treated patients, it becomes mandatory to understand whether or not 
riluzole worsens the compromised neuromuscular transmission in ALS patients, 
possibly elucidating this effect at the molecular level.  
ALS patients experience muscle denervation and reinnervation through collateral 
sprouting of healthy motor neurones (Eisen and Swash, 2001), which, among many 
other consequences, affects the composition and distribution of muscle AChR. In 
innervated fibres, receptors formed by the α1β1εδ subunits (ε-AChR) are densely 
packed at the endplate and at the myotendineous junction and virtually absent 
elsewhere (Katz and Miledi, 1964). In denervated muscle cells, AChRs are formed by 
α1β1γδ subunits (γ-AChR), with an almost uniform distribution over the entire 
sarcolemma (Witzemann et al., 1991). In ALS patients, both ε- and γ-AChR are 
present, reflecting the presence of denervated muscle fibres. 
In this work we prove that in vitro riluzole has differential effects on recombinant 
human γ- or ε-AChR and provide a characterization of its action at the single channel 
level in transfected cells and in myotubes derived from ALS patients. Moreover, we 
analyze the effect of riluzole on nerve-muscle transmission in ALS patients before 
and during a brief suspension of riluzole treatment, reaching the important conclusion 
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that treatment does not impair compound muscle action potential (CMAP) generation 
upon repetitive nerve stimulation. 
 
 
MATERIALS AND METHODS 
 
Patients recruitment and analysis 
Thirty-six patients (14 females) with probable or definite ALS according to El 
Escorial criteria were recruited and analyzed at the ALS centre of Policlinico 
Umberto I, Università Sapienza of Rome. Their mean age was 64.5 years (range: 47-
78 years). CMAPs were recorded from the abductor digiti minimi and deltoid 
muscles, by ulnar nerve stimulation at the wrist and axillary nerve at Erb's point, 
respectively. The amplitudes of the initial negative peaks of the CMAPs were 
measured and the changes in CMAPs amplitude were analyzed. Repetitive nerve 
stimulation test was performed on the axillary nerve and the ulnar nerve, with the 
recording electrode over the deltoid muscle and the abductor digiti minimi muscle, 
respectively. For each train of repetitive stimuli, the amplitudes of the first and fifth 
CMAPs were compared, and the resulting decrement of the latter expressed as 
percentage of the first. All patients were examined before and after a 1-week 
suspension of riluzole treatment; data values were compared using paired Student’s t-
test. Results were considered to be significantly different when p < 0.05.  
Needle biopsy was performed as previously described (Palma et al., 2011). The study 
was authorized by the Ethical Committee of Sapienza University and written 
informed consent to participate in the study was given by all patients.  
 
Cell culture and AChR expression in cells and oocytes 
AChR subunit cDNAs in pRBG4 were kindly provided by Dr A.G. Engel (Mayo 
Clinic, Rochester, USA).  
Human embryonic kidney 293 (HEK) cells were grown in Dulbecco's modified 
Eagle's medium (DMEM) plus 10% foetal bovine serum (both from Invitrogen, 
Carlsbad, CA) and 1% penicilline / streptomycine. Cells were plated on poly-L-
lysine-coated 35 mm Petri dishes and transiently transfected 24 h later using 
Lipofectamine 2000 (Invitrogen), adding to each dish 1 µg of each subunit cDNA 
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plus 0.5 µg cDNA encoding enhanced green fluorescent protein (EGFP). HEK cells 
were mechanically dissociated and replated onto glass coverslips 24 h before 
measurements. Routinely, cells were used for electrophysiological experiments 48 to 
72 h after transfection, as previously reported (Di Angelantonio et al., 2011). Cultures 
were maintained in a humidified incubator with 5% CO2, 37 °C. 
Human satellite cells were derived from muscle needle biopsies performed on ALS 
patients, with their written informed consent. Cells were cultured as previously 
described (Fucile et al., 2006; Palma et al. 2011); differentiation was induced at 
approximately 50% confluence by switching to a low-serum medium (DMEM plus 
2% horse serum and P/S). 
Preparation of Xenopus laevis oocytes and nuclear injection procedures were as 
detailed elsewhere (Miledi et al. 2006). Oocytes were collected under anaesthesia 
from frogs that were humanely killed after the final collection. 
 
Patch clamp recordings in cultured cells 
Currents were recorded at room temperature (23-27o C) via an Axopatch 200B 
amplifier (Molecular Devices, Union City, CA, USA), using pCLAMP9 (Molecular 
Devices). In whole-cell and outside-out recordings cells were continuously superfused 
using a gravity-driven fast exchanger perfusion system (RSC-200, Bio-Logic, 
France). Whole-cell recordings were performed in standard external solution 
containing (mM): 140 NaCl, 2.8 KCl, 2 CaCl2, 2 MgCl2, 10 HEPES/NaOH, 10 
glucose, pH 7.3. Patch pipettes (2-5 MΩ tip resistance) contained (mM): 140 CsCl, 5 
BAPTA, 10 HEPES-KOH, 2 Mg-ATP, 2 MgCl2, pH 7.3. The patch series resistance 
was compensated by 80-95% and measurements were performed at a holding 
potential of -60 mV, unless otherwise indicated. Outside-out recordings were 
performed at -80 mV using standard external medium; patch pipettes (Sylgard-coated 
for single-channel recordings) contained (mM): 90 CsCl 90, 50 CsF, 5 BAPTA, 10 
HEPES-KOH, 2 Mg-ATP, 2 MgCl2, pH 7.3. The rise-time of the ACh-evoked 
currents, measured as the interval between 10% and 90% of peak amplitude ranged 
between 0.8 and 3 ms in outside-out recordings.  
Cell-attached recordings were performed using standard external solution or a KCl-
based solution (mM): 140 KCl, 2.8 NaCl, 2 CaCl2, 2 MgCl2, 10 glucose, 10 HEPES-
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KOH, pH 7.3. Sylgard-coated patch pipettes were filled with the extracellular solution 
used plus ACh (100 nM) alone or additioned with riluzole (0.5 µM), as indicated. 
The decay phase of macroscopic ACh-evoked current (IACh) was fit using pClamp to a 
single exponential function: 
IACh(t) = Iplateau + I0 e-t/
τ      (Equation 1)  
Single channel recordings obtained under outside-out or cell-attached conditions were 
filtered at 5 KHz and sampled at 25 KHz. Data were analysed with pClamp 9, using 
50% threshold criterion, omitting events shorter than 0.12 ms, as previously described 
(Di Castro et al., 2007). In cell-attached recordings, slope conductance was calculated 
by linear fitting of the unitary amplitudes recorded at least at 3 different pipette 
potentials for each cell. For outside-out recordings, channel conductance was 
calculated dividing unitary channel amplitude by pipette potential, taking into account 
a mean reversal potential of 13 ± 3 mV (mean ± SEM, 14 patches).  
All salts were purchased from Sigma Italia (Milano, Italy). Two data sets were 
considered statistically different when P< 0.05 by ANOVA or Student's paired t test. 
 
Voltage clamp recordings in oocytes 
Membrane currents were recorded from voltage clamped oocytes 2-4 days after 
injection using two microelectrodes filled with 3 M KCl. The oocytes were placed in 
a recording chamber (volume, 0.1 ml) and perfused continuously, 8–10 ml/min, with 
oocyte Ringer’s solution (Miledi et al., 2006) at room temperature (20–22°C). Unless 
otherwise specified, oocytes were voltage-clamped at -60 mV.  
The half-inhibitory concentration (IC50) of riluzole and the ACh concentration 
producing half-maximal effect (EC50) were estimated by fitting the data to Hill 
equations, using least-square routines as previously described (Palma et al., 2002). 
IACh desensitization was measured by fitting ACh currents with Equation 1.  
 Data were analyzed using Sigma Plot software and are given as means ± SEM.; data 
sets are considered statistically different when P< 0.05. (ANOVA test).  
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RESULTS 
 
Riluzole effect on whole-cell ACh-evoked currents in HEK cells. 
We first examined the influence of riluzole on the function of recombinant human γ- 
or ε-AChR expressed in HEK cells. ACh (100 µM, 0.5 s) elicited whole cell current 
(IACh) responses in virtually all EGFP-positive cells. No consistent difference in 
current amplitude was observed between cells expressing γ- or ε-AChR, in spite of 
large cell-to cell variations (range: from -45 to - 0.5 nA at -60 mV for both AChR 
types). These currents had an exponential decay during sustained ACh applications 
(Fig. 1A) with time constants of 117 ± 10 ms (γ-AChR, n = 32) and 113 ± 6 ms (ε-
AChR, n = 23). At a concentration present in patients' serum (0.5 µM), riluzole 
coapplied with ACh had almost no effect on IACh. However, when cells expressing γ-
AChR were pretreated with riluzole before it was co-applied with ACh, current 
amplitude was decreased and its decay accelerated (Fig. 1A; see Supplementary Table 
1 for details), so that current integral (QACh), which depends on both parameters, was 
reduced. Even the briefest pretreatment tested (0.5 s) enhanced riluzole effect, which 
reached a plateau with 5 s preapplications, when QACh was reduced to about 50% of 
control value (Fig. 1B). In cells expressing ε-AChR, riluzole was less effective, as 
QACh was reduced at most to about 70% of control value  (Fig. 1B and Supplementary 
Table 1). For both γ- and ε-AChR, IACh reduction was enhanced when riluzole 
concentration was increased to 50 µM (data not shown). 
The increase of riluzole-induced effect on IACh after pretreatment might be due to its 
interference with intracellular signalling pathways that in turn modulate IACh. We 
therefore assessed the effect of riluzole in cells internally dialyzed with GDPβS, a 
non-phosphorylable analogue of GDP, which prevents G-protein activation. However, 
inclusion of GDPβS (100 µM) into the patch pipette did not interfere with the effect 
of riluzole (0.5 µM, 30 s pretreatment, Fig. 1B and C) in transfected cells expressing 
γ- or ε-AChR, arguing against a G protein-mediated action of riluzole on AChR. 
 
Block of ACh-evoked currents in oocytes 
Riluzole-induced reduction of IACh in cells expressing γ-AChR was similar to that 
observed in human myotubes (Palma et al., 2011), suggesting that the expression 
system used does not influence riluzole action. This point was further tested in 
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Xenopus oocytes expressing γ- or ε-AChR (Fig. 2). Application of ACh to these cells 
(1 µM to 1 mM for 4 s) elicited inward currents (IACh) with peak amplitude depending 
on transmitter concentration, whereas non-injected oocytes showed no detectable 
responses to ACh. In oocytes expressing ε-AChR, ACh at 50 µM elicited a current 
with mean peak amplitude of -2.8 ± 0.9 µA (-60 mV; 24 oocytes/ 4 frogs; 24/4). 
Currents of similar amplitude (-1.7 ± 0.4 µA; 22/4) were recorded from oocytes 
expressing γ-AChR. As in HEK cells, riluzole affected IACh and the block was 
enhanced if the drug was applied before ACh. In oocytes, the plateau was attained at 
120 s of pretreatment, which was used in all experiments described below. Riluzole-
induced inhibition of IACh was more potent in oocytes expressing γ-AChRs than ε-
AChRs, as shown by concentration-response curves (Fig. 2) that yielded IC50 values 
of 8.0 ± 1.1 µM (n = 8/3) and 55.6 ± 0.7 µM (n = 10/3), respectively (P = 0.00001); 
nH was about 1.5 for both AChR isoforms. For both AChR types, the effect of riluzole 
was voltage-independent in the range -100 to + 20 mV (8 oocytes each; data not 
shown). 
In oocytes expressing ε-AChR the decay of IACh was not modified by riluzole at its 
IC50 (50 µM), as τdecay was 1.7 ± 0.3 s and 1.5 ± 0.4 s (n = 8/3; P=0.3) before and in 
the presence of riluzole, respectively. By contrast, in oocytes expressing γ-AChR the 
riluzole-induced decrease of IACh was accompanied by a significant change in current 
decay, as τdecay was 1.8 ± 0.2 s (n = 8/3) under control conditions and, in the same 
oocytes, it became 0.7 ± 0.1 s (P=0.002) during treatment with riluzole (10 µM), 
resembling the effect described in transfected HEK cells. 
The block of IACh was independent of ACh concentration (1 µM to 1 mM) to and 
riluzole (50 µM) did not affect the potency of ACh on γ- or ε-AChR, since ACh 
concentration - current response relationships yielded similar values of EC50 and nH 
(16.7 ± 1.1 µM and 1.1 ± 0.1, n=6/2 for ε-AChR; 21.5 ± 0.2 µM and 1.6 ± 0.2, n=6/2 
for γ-AChR) before and during riluzole treatment (data not shown). These 
observations suggest that the riluzole-induced acceleration of current decay is not 
related to a change in neurotransmitter potency.  
 
Effect on unitary ACh-evoked events in HEK cells and human myotubes 
The mechanism of riluzole action on IACh was investigated analysing unitary ACh-
evoked events either in the cell attached or outside-out configuration. Outside-out 
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recordings were performed on HEK cells expressing γ- or ε-AChR, subsequently 
exposed to ACh (100 nM at -80 mV) or ACh plus riluzole (0.5 µM), with at least 10 s 
wash between applications. In each patch, unitary events evoked by ACh alone or 
plus riluzole had identical conductance (39.6 ± 0.7 pS, n=11 for γ-AChR; 50.0 ± 1.0, 
n=7 for ε-AChR) and open time distribution (Table 1). However, in the presence of 
riluzole, closed time histograms were shifted to the right in all patches, as compared 
to control conditions (Figure 3), although only the third and fourth (for γ-AChR) best 
fitting exponential components were significantly prolonged (Table 1). Riluzole-
induced increase of channel closed duration was not an artefact due to channel run-
down, as in most patches closed times reversed towards control values when ACh was 
applied alone for a second time (data not shown). It must be noted that in these 
experiments, riluzole preapplication was not used, but the initial 5-10 s of the 
recordings, when multiple ACh-induced openings occurred, were not considered for 
analysis.  
To check that riluzole effect is not influenced by patch excision, we performed cell-
attached recordings on HEK cells expressing γ-AChR, including riluzole (0.5 µM) in 
the patch pipette. Again, unitary channel conductance was identical in control and 
riluzole-exposed patches (34.0 ± 3.1 pS and 32.2 ± 0.9 pS, respectively; n=7 for 
both). The distribution of open durations was adequately fitted by 2 exponential 
components with similar time constants in the two experimental groups (Figure 4A; 
details in Supplementary Table 2). Closed time distribution was widely variable for 
both control and treated cells, and could not be reliably compared. Cell-attached 
recordings were performed also on myotubes from ALS patients (Figure 4B) and 
yielded analogous results. In these cells, most experiments were performed bathing 
cells in KCl-based extracellular solution. Channel conductance was 35.7 ± 1.1 pS 
(n=13) under control conditions and 33.0± 3.1 pS (n=7) with riluzole. In both control 
and riluzole-exposed patches, open time distributions were fitted by 2 exponential 
components with time constants similar to those observed in HEK cells, and not 
influenced by the drug (Figure 4B; details in Supplementary Table 2).  
 
How fast is riluzole action? 
During neuromuscular transmission, nerve-released ACh is present in the synaptic 
cleft only for few ms before being hydrolyzed by acetylcholinesterase. The action of 
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riluzole on such a fast time scale cannot be inferred from whole-cell recordings, as 
rise-time of ACh-evoked currents is in the order of 10-20 ms. Macroscopic ACh-
evoked currents from outside-out patches have a much shorter rise time, and we could 
assess the effect of riluzole (0.5 µM, 30 s pretreatment) within few ms of ACh (100 
µM) application (Figure 5). In membrane patches expressing ε-AChR, in the presence 
of riluzole QACh was 96 ± 3 % (n=8) of control value after 10 ms of ACh application 
but it was significantly reduced to 83 ± 6 % (n=8, P=0.02) at 100 ms, indicating that 
the action of the drug develops slowly. For γ-AChR, QACh was significantly reduced 
to 79 ± 4 % of control value (n=6, P=0.002) at 10 ms and to 66 ± 3 % (n=6, 
P=0.0001) at 100 ms.  
 
Riluzole does not affect CMAPs in ALS patients 
To examine if riluzole as used in clinical practice affects neuromuscular transmission, 
we examined 36 ALS patients, measuring the amplitude of compound muscle action 
potentials (CMAPs) elicited by repetitive nerve stimulation (RNS), which provides a 
sensitive and non-invasive assay of neuromuscular transmission. Patients were tested 
immediately before and after 1-week suspension of riluzole treatment, a time that 
allows for adequate riluzole washout, which has been estimated at about 40 hours (Le 
Liboux et al., 1999; Chandu et al., 2010). The test was performed on two different 
nerve-muscle groups. After the week of riluzole washout, CMAP amplitude did not 
change significantly in any of the patients examined, showing that no further axonal 
depletion occurred between the two neurophysiological evaluations. The decrease of 
CMAP amplitude during RNS was also not statistically different at the end of the 
riluzole washout period as compared to the control value, for both the ulnar and the 
axillary nerves (Figure 6). Thus, riluzole treatment appears to be devoid of 
detrimental effects at least on this estimator of neuromuscular transmission. 
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DISCUSSION 
The results of this paper disclose a differential effect of riluzole on recombinant 
human γ-AChR and ε-AChR, expressed in HEK cells or oocytes. In both cell systems, 
riluzole-induced block was faster and stronger for γ-AChR than for ε-AChR, although 
with kinetic differences between the two cell types, likely due to the large size and 
complex membrane of oocytes as compared to HEK cells. In outside-out recordings, 
the synaptic AChR isoform was blocked by riluzole only with ACh applications far 
outlasting the typical duration of synaptic events, allowing the hypothesis that riluzole 
at clinical concentrations should not impair endplate function. This supposition was 
verified in vivo, measuring CMAPs elicited by nerve stimulation in ALS patients, to 
determine the efficiency of neuromuscular transmission. In agreement with our 
hypothesis, muscle response to nerve stimulation was not influenced by 1-week 
suspension of riluzole treatment, which produces complete washout of plasma riluzole 
(Le Liboux et al., 1999; Chandu et al., 2010). Furthermore, the absence of effects on 
CMAPs evoked by repetitive nerve stimulation suggests that clinical use of riluzole 
does not affect the safety factor at the neuromuscular junction in treated patients. 
As previously seen in human tissue (Palma et al., 2011), we show here that 
preapplication of riluzole increases the block of IACh in cells expressing recombinant 
γ- or ε-AChR. This observation raises the possibility that intracellular signalling 
pathways mediate riluzole-induced block of AChR. For instance, in neuronal 
membranes riluzole blocks PKC (Noh et al., 2000). However, in transfected HEK 
cells, riluzole effect was preserved upon patch excision or blockade of G-proteins by 
the classical inhibitor GDPβS, indicating that soluble intracellular factors and G-
proteins are not involved in the transduction of riluzole effect. Moreover, the effect on 
IACh was observed in experimental systems as diverse as cDNA-injected oocytes (this 
work) and cultured human myotubes (Palma et al., 2011), which seems to be more 
consistent with a direct action of riluzole on AChR than with the transduction by a 
second messenger.  
Being independent of ACh concentration, at least in oocytes, riluzole-induced block 
of IACh appears to be due to a non-competitive mechanism of action. Open-channel 
block is an unlikely candidate, as riluzole has a voltage-independent effect and does 
not influence the duration of ACh-evoked channel openings, the two hallmarks of 
open-channel blockade (Neher and Steinbach, 1978). In oocytes, riluzole did not 
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change ACh potency at γ- or ε-AChR, suggesting that ACh binding and channel 
gating are largely unaltered for both receptors (Colquhoun, 1998); therefore AChR 
desensitization was likely the functional parameter affected by riluzole. Single-
channel recordings showed that riluzole had no effect on the conductance and open 
time distribution of ACh-evoked channels, but prolonged closed intervals, supporting 
the hypothesis that it acts by stabilizing AChR desensitized state(s), with no effect on 
the open state. Such an action has already been proposed for other substances, which 
have an enhanced effect on AChR channels following preapplication, for instance 3-
(trifluoromethyl)-3-(m-iodophenyl)diazirine, some local anesthetics and verapamil 
(Forman, 1999; Spitzmaul et al., 2009; Moriconi et al., 2010; ) 
Both in oocytes and in HEK cells, riluzole blocked the γ-AChR more than the ε-
AChR, thus adding to the list of compounds having differential actions on the two 
isoforms of muscle AChR. For instance, the γ-AChR is more sensitive than the ε-
AChR to block by 5-hydroxytryptamine (Grassi, 1999) or hydrocortisone (Bouzat and 
Barrantes, 1996); fluoxetine alters channel kinetics of the γ-AChR (Garcia-Colunga et 
al., 1997) but not the ε-AChR (Harper et al., 2003). More striking, d-tubocurarine at 
low concentrations is a blocker of ε-AChR, but a weak agonist of γ-AChR (Steinbach 
and Chen, 1995).  
While we show that riluzole-induced block of ε-AChR is unlikely to occur during 
neuromuscular transmission, blockade of γ-AChR may play some role in disease 
history. Since muscle fibres of ALS patients undergo denervation and subsequent 
reinnervation by collateral sprouting of healthy motor neurones (Eisen and Swash, 
2001), the γ-AChR isoform may transiently coexist with ε-AChR at reinnervated 
endplates, as it happens in rodents  (Yampolsky et al., 2010). However, also for γ-
AChR, brief ACh-evoked currents were little affected by clinical concentrations of 
riluzole, again suggesting that synaptic transmission is unlikely to be impaired. In 
non-innervated muscles, activation of extrasynaptic γ-AChR might be induced by the 
tonic release of ACh or an ACh-like compound, well documented in cultured 
myotubes and denervated muscle in vivo (Krnjevic and Straughan, 1964; Krause et 
al., 1995; Bandi et al., 2005). Whether or not γ-AChRs influence muscle reinnervation 
in humans is unknown; in rodents reinnervation of partially denervated muscles is 
impaired by α-bungarotoxin (Connold and Vrbova, 1991). Other studies, however, 
point out that full chronic AChR blockade is required to prevent collateral sprouting 
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of motor axons (Pestronk and Drachmann, 1985), so that the partial riluzole-induced 
reduction of AChR function might be non detrimental to the reinnervation process, an 
hypothesis that deserves analysis in adequate experimental systems. On the other 
hand, it has long been known that, during chick and mouse development, blockade or 
reduction of γ-AChR favours motor neuron survival (Oppenheim et al., 2000; Terrado 
et al., 2001; Liu et al., 2008; Yampolsky et al., 2008), thus allowing the suggestion 
that riluzole action might be beneficial against ongoing motor neuron degeneration 
through this route, too.  
At present, the idea that muscle denervation may precede -or even contribute to- 
motor neuron death is gaining support (as reviewed by Musarò, 2010; Dadon-Nachum 
et al., 2011), so that investigation of the physiological consequences of riluzole-
induce blockade of γ-AChR warrants further studies to understand whether it 
contributes, positively or negatively, to disease progression.  
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Table 1: Riluzole action on AChR-channel kinetics in outside-out patches. 
 
 ε-AChR (7 patches) γ-AChR (11 patches) 
 Control Riluzole Control Riluzole 
τopen1 (ms) 
(aopen1) (%) 
0.50 ±0.05  
(55 ± 5) 
0.50± 0.02 
(45 ± 5) 
0.7 ±0.1 
(40 ± 2) 
0.7 ± 0.1 
(40 ± 2) 
τopen2 (ms) 
(aopen2) (%) 
1.8 ± 0.2 
(45 ± 5) 
1.7 ± 0.1 
(55±5) 
3.5 ± 0.4 
(60 ± 2) 
3.9 ± 0.5 
(60 ± 2) 
τclosed1 (ms) 
(aclosed1) (%) 
0.20 ± 0.02 
(16 ± 1 
0.30 ± 0.06 
(20 ± 3) 
0.20 ± 0.08 
(21 ± 3) 
0.5 ± 0.2 
(8 ± 1) 
τclosed2 (ms) 
(aclosed2) (%) 
1.8 ± 0.3 
(34 ± 3) 
2.8 ± 0.5 
(31 ± 5) 
3.9 ± 0.9 
(22 ± 4) 
6.2 ± 1.1 
(21 ± 4) 
τclosed3 (ms) 
(aclosed3) (%) 
8.7 ± 1.9 
(48 ± 2) 
18 ± 5 * 
(47 ± 4) 
33 ± 6  
(39 ± 3) 
61 ± 12 * 
(43 ± 3) 
τclosed4 (ms) 
(aclosed4) (%) 
  219 ± 50 
(23 ± 4) 
420 ± 100*  
(31 ± 7) 
 
τopen (aopen) and τclosed (aclosed): time constants (weight) of the exponential components 
best fitting the distribution of open and closed durations, respectively. Data are given 
as mean ± S.E.M. for the indicated number of patches, each exposed to ACh (100 nM, 
-80 mV) alone and to ACh plus riluzole (0.5 µM). *: Significantly larger than control 
(P<0.04, paired Student's t test) 
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FIGURES AND LEGENDS 
 
 
 
Figure 1. Effect of riluzole on ACh-evoked whole-cell currents in HEK cells.  
A, typical whole-cell currents evoked by ACh (100 µM, horizontal bar) alone (C) or 
in the presence of riluzole (R; 0.5 µM, 30 s pre-treatment) in cells expressing the 
indicated AChR type. B, duration of pre-treatment with riluzole (0.5 µM) enhances its 
effect in cells expressing γ- or ε-AChR as indicated (filled symbols: inclusion of 
GDPβS into the patch pipette). The integral of current response (QACh or QACh+riluzole) 
was calculated over the entire duration of ACh (100 µM) application; riluzole effect 
was quantified by the ratio QACh+riluzole/QACh in each cell (4 to 10 for each point). Grey 
line represents the exponential best fit of the experimental points. C, typical whole-
cell currents evoked by ACh alone or plus riluzole (as in A) when GDPβS (100 µM) 
was included the patch pipette. Notice that riluzole effect is preserved. In all panels, 
holding potential, -60 mV.  
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Figure 2. Inhibition of ACh-evoked currents by riluzole in oocytes.  
A, typical currents evoked by ACh (horizontal bars) alone (C) or together with 
riluzole (R; 50 µM for ε-AChR; 10 µM for γ-AChR; 120 s pretreatment for both) in 
two oocytes expressing AChRs as indicated. B, plot of relative amplitude of currents 
evoked by ACh (50 µM, -60 mV) plus riluzole at various concentrations (120 s 
pretreatment), expressed as percent of control current (ACh alone) in the same cell, 
for oocytes expressing γ-AChR (□, 8/3) or ε-AChR (○, 10/3). IC50 and nH were 8.0 ± 
1.1 µM and 1.5 ± 0.2 (γ-AChR); 55.6 ± 0.7 µM and 1.5 ± 0.3 (ε-AChR).  
 22 
 
 
Figure 3. Effect of riluzole on unitary ACh-evoked currents in outside-out patches. 
A and B, unitary events evoked by ACh (100 nM, -80 mV) in outside-out patches 
expressing γ-AChR (A) or ε-AChR (B), sequentially exposed to ACh alone (control) 
or plus riluzole (0.5 µM), as indicated. Bottom panels represent the histograms of 
channel closed times, obtained in the recordings shown above, best fitted with four (γ-
AChR) or three (ε-AChR) exponential components. Notice the lengthening of the 
closed times in the presence of riluzole, as compared to control conditions. Channel 
openings represented by downward deflections. 
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Figure 4. Effect of riluzole in cell-attached recordings.  
A, typical cell-attached recordings in two different HEK cells expressing γ-AChR, 
including in the patch pipette ACh (100 nM) alone (slope conductance, 31 pS) or plus 
riluzole (0.5 µM; slope conductance, 34 pS), as indicated. Bottom, the histograms of 
channel open durations, obtained in the same recordings, were best fitted by two 
exponential components, with time constants τop1 = 1.5 ms (33%) and τop2 = 9.5 ms 
(67%) for control; 1.1 ms (35%) and 7.4 ms (65%) in presence of riluzole. B, cell-
attached recording of unitary events in two different patches on the same myotube 
from an ALS patient, using ACh (100 nM) alone or plus riluzole, as indicated. 
Channel conductance was 30 pS (control) or 34 pS (+ riluzole). Bottom, the 
corresponding histograms of channel opening durations, best fitted by two 
exponential components with τop1 = 1.4 ms (39%) and τop2 = 12.7 ms (61%) in control 
conditions, 1.8 ms (36%) and 11.7 ms (64%) in the presence of riluzole. In all panels, 
channel openings are represented by upward deflections; cells were bathed in standard 
external solution. 
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Figure 5. Effect of riluzole during fast ACh applications.  
A, superimposed currents evoked by sequential applications of ACh (100 µM, 100 
ms) alone (C) or together with riluzole (R; 0.5 µM, 30 s pre-treatment) to outside-out 
patches from HEK cells expressing γ- or ε-AChR, as indicated. B, bar graphs 
representing relative current integral during 10, 20 and 100 ms from ACh application. 
For γ-AChR, riluzole-induced reduction of QACh was significant already at 10 ms (*: 
P < 0.002); for ε-AChR, current integral was significantly reduced only at 100 ms (*: 
P=0.02). In all panels, holding potential, -60 mV. 
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Figure 6. Riluzole has no effect on neuromuscular transmission in ALS patients. 
A and B, Superimposed traces representing 10 CMAPs evoked by repetitive 
stimulation of the ulnar (A) and axillary nerve (B) in a patient, during riluzole 
treatment (left) and at the end of a 1-week medicament washout. Notice that CMAP 
amplitude remains constant in this individual. C, dispersion plot of CMAP evoked by 
the 5th stimulus, expressed as percent of the amplitude of the 1st response, for all 36 
patients considered in the study. Boxes represent mean ± 95% confidence interval of 
all values. For both ulnar and axillary nerves, values were not modified by riluzole 
washout (P> 0.9). 
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Supplementary Table 1: Pre-application of riluzole increases its effect on IACh 
amplitude and decay.  
 ε-AChR γ-AChR 
Pretreatment (s) Amplitude (%) τdecay (%) Amplitude (%) τdecay (%) 
0  100 ± 3 (n=7) 83 ± 4 92±5 (n=7) 97±2 
0.5  87, 81 70, 79 78±3 (n=10)* 100±5 
1  NA NA 67±2 (n=10)# 81±2# 
5  88±6 (n=4) 89±3* 54±5 (n=9)# 74±3# 
10  93±7 (n=5) 80±3# 55±5 (n=8)* 75±3* 
30 
+GDPβS  
86±3 (n=5)* 
84±5 (n=5)* 
71±4# 
69 ± 4* 
72±4 (n=14)# 
70±10* (n=4) 
75±3# 
63±2# 
60  NA NA 69±5 (n=12)# 73±2# 
120  97 ± 3 (n=6) 79 ± 8 * 69±6 (n=8)# 73±3# 
 
Data are mean ± SEM values (number of cells tested) of the amplitude and decay time 
constant (tdecay) of whole-cell currents elicited by ACh (100 µM at -60 mV) in HEK 
cells expressing the indicated AChR type. Values obtained in the continuous presence 
of riluzole (0.5 µM), preapplied for the indicated amount of time, are expressed as 
percent of the values obtained under control conditions (ACh alone) in each cell. 
Comparison of data obtained with riluzole vs. control values was tested using paired 
Student's t test; *: P<0.05; #: P < 0.005,  
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Supplementary Table 2: Open channel distribution in cell-attached recordings 
 
 HEK cells ALS myotubes 
 τ1 (ms) 
(a1) (%) 
τ 2 (ms) 
(a2) (%) 
τ1 (ms) 
(a1) (%) 
τ2 (ms) 
(a2) (%) 
Control 1.4 ± 0.1 (n=6) 
(33 ± 4) 
7.0 ± 0.7 
(67 ± 4) 
1.2 ± 0.1 (n=5) 
(34 ± 2) 
9.4 ± 0.5 
(66 ± 3) 
riluzole 1.4 ± 0.2 (n=7) 
(43 ± 4) 
7.6 ± 0.8 
(57 ± 4) 
2.0 ± 0.5 (n=7) 
(38 ± 5) 
12.2 ± 0.9  
(62 ± 5) 
 
τ1 (a1) and τ2 (a2): time constants (weight) of the two exponential components best 
fitting the distribution of channel open durations, in HEK cells transfected with γ-
AChR or in myotubes derived from satellite cells of ALS patients. Data are given as 
mean ± S.E.M. for the indicated number of patches, each exposed to ACh (100 nM, -
80 mV) alone or to ACh plus riluzole (0.5 µM). In both cell types, values obtained 
with riluzole were not significantly different (P > 0.06) from the corresponding values 
in control recordings. 
 
